What is CONTINUUMRX?
ContinuumRx operates at the intersection of clinical excellence and logistical efficiency, providing comprehensive infusion services that bridge the gap between hospital discharge and long-term recovery. With over two decades of industry experience, the company has established itself as a vital partner for healthcare systems seeking to optimize post-acute care coordination. Their service portfolio is extensive, covering high-acuity needs such as IVIG therapy, heart failure management, and biologic therapies. Accredited by the Accreditation Commission for Health Care (ACHC), the organization maintains rigorous quality standards, positioning itself as a trusted provider in a highly regulated and essential healthcare niche.
How much funding has CONTINUUMRX raised?
CONTINUUMRX has raised a total of $21.5M across 3 funding rounds:
Unspecified
$7M
Private Equity
$13.5M
Debt
$1M
Unspecified (2012): $7M with participation from Redmont Venture Partners, Mitsui & Co, Health Enterprise Partners, and Stonehenge Capital
Private Equity (2015): $13.5M led by NewSpring Capital
Debt (2020): $1M supported by PPP
Key Investors in CONTINUUMRX
Mitsui & Co
Mitsui & Co. is a global trading and investment company that leverages its cross-industry expertise to support healthcare solutions and enhance quality of life through sustainable value creation.
Health Enterprise Partners
HEP Fund is a specialized investment firm that partners with organizations transforming the healthcare industry, backed by a network of strategic payer and provider limited partners.
Redmont Venture Partners
Redmont Venture Partners is a strategic investment firm focused on partnering with visionary founders to build impactful businesses through sustainable growth and tailored advisory services.
What's next for CONTINUUMRX?
With the recent influx of capital, ContinuumRx is well-positioned to accelerate its strategic initiatives, focusing on the integration of advanced care management technologies and the expansion of its clinical network. The company's roadmap likely involves deepening its partnerships with major health systems to streamline the transition of care, thereby reducing readmission rates and improving patient outcomes. As the demand for home-based medical services continues to rise, ContinuumRx is poised to leverage its established infrastructure to capture additional market share, potentially exploring new therapeutic modalities or geographic expansion to further solidify its leadership in the infusion therapy market.
See full CONTINUUMRX company page
